POSB403 Reimbursed Cost for Monoclonal Antibodies in Bulgaria: A Case with Adalimumab and Pembrolizumab
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.1266
https://www.valueinhealthjournal.com/article/S1098-3015(21)03061-8/fulltext
Title :
POSB403 Reimbursed Cost for Monoclonal Antibodies in Bulgaria: A Case with Adalimumab and Pembrolizumab
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)03061-8&doi=10.1016/j.jval.2021.11.1266
First page :
Section Title :
Open access? :
No
Section Order :
10803